Can Dose Spacing of IL-17i Maintain Efficacy in Psoriasis?
Dose spacing of interleukin-17 (IL-17) inhibitors maintained therapeutic efficacy in patients with stable psoriasis, with no substantial differences observed between secukinumab and brodalumab and acceptable survival of the dose-spacing regimen for up to 12 months.
METHODOLOGY:
This retrospective cohort study analysed the effectiveness and survival of patients with psoriasis undergoing therapeutic biologic dose spacing of secukinumab or brodalumab.
The analysis included 80 patients; 38.75% of them received secukinumab and 61.25% received brodalumab.
Dose spacing was defined as extending secukinumab dosing to every 6 weeks and brodalumab to every 3 weeks after induction. All patients underwent 50% dose spacing of the approved range after a mean treatment duration of 35 months.
Researchers monitored mean Psoriasis Area Severity Index (PASI) scores, PASI100, PASI90, and PASI ≤ 1. The mean follow-up duration under the dose-spacing regimen was 6.7 months.
TAKEAWAY:
The mean PASI value was 0.7 after 3 months of dose spacing and 0.1 after 12 months. No significant differences in mean PASI scores were observed between secukinumab and brodalumab at any timepoint after dose spacing.
PASI100 achievement was 91.25% at dose-spacing initiation and remained stable throughout the following year; 99% of patients achieved PASI90 and 100% achieved PASI ≤ 1 at dose-spacing initiation, and both rates were maintained at 12 months.
The 12-month drug survival rate for the dose-spacing regimen was 66.1%, with 25% of patients returning to standard dosage and 66.7% of these cases regaining PASI100.
Secukinumab demonstrated higher drug survival after dose spacing than brodalumab (78.3% vs 58.9%).
IN PRACTICE:
"No significant differences in effectiveness were found between secukinumab and brodalumab in patients undergoing a D-S [dose-spacing] regimen. Overall, dose de-escalation of IL-17 inhibitors in patients with psoriasis who have achieved a stable response seems an effective therapeutic strategy, even if 2 of 5 patients returned to the original regimen after 1 year. When coming back to the standard regimen after D-S, PASI was regained by two-thirds of patients after 6 months," the authors of the study wrote.
SOURCE:
This study was led by Luca Mastorino, Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy. It was published online on June 12, 2025, in Clinical and Experimental Dermatology .
LIMITATIONS:
The study's real-life design and retrospective nature may have introduced potential biases. The relatively small sample size could have affected the generalisability of the findings. The analysis of observed cases may have affected the interpretation of long-term outcomes.
DISCLOSURES:
This study did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors reported having no relevant conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Republican who blamed the political left for her near-fatal ectopic pregnancy now says she's facing death threats
Florida Republican Rep. Kat Cammack has revealed that her offices had to be evacuated on Wednesday after she received 'imminent death threats' in response to comments she made last week about the treatment of her ectopic pregnancy in 2024. Cammack, 37, told The Wall Street Journal about her ordeal in a Florida emergency room after it was discovered that her baby's embryo was implanted where the fallopian tube meets the uterus, meaning it could not survive and that her own life was in danger without action. Writing on X on Wednesday evening, Cammack, who is pregnant again and due in August, recounted the disturbing backlash she had received in response to the article, posting screenshots of abusive messages she had been sent. 'Today, we had to evacuate our offices due to imminent death threats against me, my unborn child, my family, and my staff. These threats erupted after the Wall Street Journal reported on my life-threatening ectopic pregnancy – a nonviable pregnancy with no heartbeat,' she explained. 'Since then, we've received thousands of hate-filled messages and dozens of credible threats from pro-abortion activists, which law enforcement is actively investigating. In light of recent violence against elected officials, these threats are taken very seriously. 'To those spreading misinformation: I did not vote for Florida's heartbeat law; I serve in the U.S. House of Representatives, not the Florida Legislature. 'Let me be clear: I will not be intimidated. I won't back down in the fight for women and families. Ensuring women have the resources and care they deserve is critical. We need real conversations about maternal healthcare in America – conversations based on truth, not fear.' ABC News's Florida affiliate has reported that it was Cammack's Washington, D.C., offices that were evacuated in response to the threats, rather than her Sunshine State premises, and that the U.S. Capitol Police are investigating. A follow-up statement from her office declared: 'Congresswoman Cammack highlighted the critical women's health crisis in America, particularly the shortage of maternal health resources and the risks of politicizing healthcare. 'Her personal story illustrates how treating women's health as a political issue endangers lives. Misinformation campaigns, funded by pro-abortion groups, have intentionally confused healthcare providers despite the law being clear on exceptions; rape, incest, victims of trafficking and life of the mother. These dangerous pro-abortion ads contributed to delays that endangered her life. 'Since the Wall Street Journal article, she has received dozens of credible death threats against herself, her unborn child, and her family, which are being investigated by U.S. Capitol Police. 'Cammack's experience underscores the unacceptable reality that sharing a personal health story in an effort to improve women's healthcare can lead to violence and intimidation. Women deserve better, as does the national healthcare dialogue.' After deciding against surgery last year during her pregnancy, the hospital's doctors and nurses had to be persuaded to give her the shot of methotrexate she required to expel the pregnancy because, she said, they feared criminal prosecution under the state's six-week abortion ban, even though she was only five weeks pregnant at the time. The procedure in question was not an abortion. Surprisingly, the congresswoman did not take issue with the ban but instead blamed the medics' hesitance on scaremongering by Democrats.
Yahoo
26 minutes ago
- Yahoo
Here's Why Cigna Group (CI) Surged in Q1
Parnassus Investments, an investment management company, released the 'Parnassus Core Equity Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund (Investor Shares) fell -2.44% (net of fees) in the quarter, outperforming the S&P 500 Index's -4.27% return. U.S. equities fell in the first quarter, showing a shift from the robust gains of the previous quarter. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Parnassus Core Equity Fund highlighted stocks such as The Cigna Group (NYSE:CI). The Cigna Group (NYSE:CI) is a US-based insurance company that offers insurance and related products and services. The one-month return of The Cigna Group (NYSE:CI) was 1.27%, and its shares lost 5.43% of their value over the last 52 weeks. On June 25, 2025, The Cigna Group (NYSE:CI) stock closed at $316.00 per share, with a market capitalization of $84.417 billion. Parnassus Core Equity Fund stated the following regarding The Cigna Group (NYSE:CI) in its Q1 2025 investor letter: "The Cigna Group (NYSE:CI), a manager of health care plans, benefited from the market's perception that it is a more stable investment option than other health insurance companies in the current environment, given its minimal exposure to federal government spending and relatively low exposure to insurance risk." A hospital technician using a laptop to review health benefit plans of a patient in the ward. The Cigna Group (NYSE:CI) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 74 hedge fund portfolios held The Cigna Group (NYSE:CI) at the end of the first quarter, which was 72 in the previous quarter. While we acknowledge the potential of The Cigna Group (NYSE:CI) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered The Cigna Group (NYSE:CI) and shared billionaire Leon Cooperman's stock picks with huge upside potential. The Cigna Group (NYSE:CI) detracted from Parnassus Core Equity Fund's performance in the fourth quarter and 2024. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
30 minutes ago
- Yahoo
Five common types of medication that make it hard to cope in the heat
As temperatures rise, so does the risk of heat-related illness, especially for people taking certain prescription drugs. The body uses several mechanisms to regulate temperature: sweating, blood flow to the skin and fluid balance. But some commonly prescribed drugs interfere with these processes, making it harder to stay cool. Here are a few you should know about this summer: Two specific types of antidepressants – selective serotonin reuptake inhibitors (SSRIs) and tricyclics (TCAs) – may make summer harder to cope with. They could even cause heat intolerance due to how they affect the body's ability to sweat. Both these antidepressants are believed to partly work by affecting neurotransmitter levels in the brain – primarily serotonin and noradrenaline. However, they may also affect other neurotransmitters. For instance, TCAs can block acetylcholine, a neurotransmitter important for sweating. This may cause some patients to sweat less. On a hot day, this could make it hard to cool down. However, TCAs also increase noradrenaline levels, a neurotransmitter that stimulates sweat glands. This can increase sweating. In fact, both SSRIs and TCAs can increase sweating in users. Data shows up to 14% of antidepressant users experience this side-effect. SSRIs may also interfere with the hypothalamus – the brain region that controls body temperature and tells the sweat glands to start producing sweat. But this signal may be affected by the increased serotonin levels. Since sweating is a key cooling mechanism, any disruptions to this process can lead to heat-related illness. Excess sweating may also cause dehydration if fluids aren't replaced. Antipsychotics are used to treat psychosis, which can occur in schizophrenia and bipolar disorder. They do this by blocking the neurotransmitter dopamine – which in turn affects levels of the neurotransmitter serotonin. This can disrupt the hypothalamus's ability to sense and respond to body temperature changes. As a result, someone taking an antipsychotic might not feel overheated or thirsty when it's hot out. This can cause low blood pressure and reduced heart function. The body then tries to compensate by narrowing the blood vessels and holding in heat. This, in turn, reduces sweating and makes it harder to cool down properly. Additionally, antipsychotics have anticholinergic properties. This means they block the action of acetylcholine, making it harder to sweat. Beta-blockers are used to manage heart failure and arrhythmias. They do this by lowering the heart rate and reducing how forcefully the heart pumps. But this can limit blood flow to the skin, making it harder for the body to release heat on hot days. Diuretics are also commonly used in the treatment of high blood pressure or heart failure. But as these drugs increase urine output, this may lead to dehydration and electrolyte imbalances during hot weather. With less fluid available, the body may struggle to sweat properly. If you become severely dehydrated, you might actually stop feeling thirsty. Blood pressure can also drop, which may cause dizziness or fainting – especially when standing up. Ramipril and losartan, also used to manage blood pressure, can increase the risk of dehydration as well. These drugs block a system in the body that helps control blood pressure, fluid balance and thirst. This may reduce your natural urge to drink, increasing dehydration risk when it's hot. Stimulants – such as the amphetamines used for ADHD – affect many brain chemicals, including dopamine and noradrenaline. This can increase body temperature, boost metabolism and change how the body sweats – all of which can make it harder to cool down, especially when exercising or in hot weather. This can also potentially lead to dehydration, overheating or even heatstroke. Stimulants may also reduce the feeling of tiredness, which can cause people to overexert themselves without realising the danger. However, some recent research shows people with ADHD who take stimulants may actually have a lower chance of heat-related illnesses – but larger trials are needed to investigate further. The researchers hypothesise that this protective effect may be due to factors such as lower body weight and users staying hydrated. Warm temperatures cause the body's blood vessels to dilate (widen) in order to help us cool off. But this action means insulin is absorbed into the bloodstream faster, as there's enhanced blood flow to the area where insulin is injected, making blood sugar drop more quickly. This can lead to hypoglycemia (low blood glucose level), which may lead to dizziness, shaking, sweating, irritability and even potentially loss of consciousness or seizures. Faster insulin absorption can also make it harder for people with diabetes to notice signs of low blood sugar in the heat, since common symptoms may be mistaken for being hot. Heat can also degrade insulin, reducing its effectiveness and making it unsafe. This is why insulin should be stored in the fridge until use – especially in summer. Damaged insulin will change appearance – turning cloudy or changing colour. Older adults, people with chronic conditions (especially those with heart or lung disease) and those taking multiple prescription drugs are especially vulnerable to heat-related illnesses. Fortunately, there are steps you can take to stay safe during summer if you're taking one of these common prescription drugs. First, check labels for storage instructions. Avoid leaving medications in hot places, such as in cars or on windowsills. Insulin isn't the only drug affected by heat – inhalers and EpiPens can also malfunction or become less effective. Second, stay hydrated when it's hot – unless your doctor has advised otherwise. Dehydration can actually worsen the effects of many medicines. For example, anti-inflammatory painkillers (such as ibuprofen) are more likely to cause kidney problems and bipolar medicines (including lithium) can become toxic if you're dehydrated. Avoid peak heat hours and stay in cool environments when possible. Watch for warning signs of heat-related illness – such as dizziness, confusion, nausea or excessive sweating. Last, don't stop taking your prescription medication without medical advice. If it's affecting your ability to cope with the heat, speak with your doctor or pharmacist. Dipa Kamdar is a Senior Lecturer in Pharmacy Practice at Kingston University. This article is republished from The Conversation under a Creative Commons license. Read the original article.
